ChartMill · Oct 9, 2026
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability
Halozyme (HALO) scores high on value and profitability in the Decent Value screen, with a cheap forward P/E, strong ROIC, but leverage risks.
HA
NASDAQ · HALO
Halozyme Therapeutics, Inc.
Healthcare · Biotechnology
$109.62
Up+$7.20 (+6.57%)
Updated Oct 15, 2026, 12:02 AM
SID Score
7.4/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.28B
- P/E ratio
- 12.19
- Dividend yield
- 0.00%
- 52-week range
- $61.23 – $116.85
- Volume
- 1.78M
- Avg. volume
- 2.52M
Price performance · HALO
HALO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
HALO closed at $109.62 after 20 trading sessions, up 1.09% for the selected period.
- Last close
- $109.62
- Period change
- +1.09%
- Period low
- $106.94
- Period high
- $115.22
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $111.92 | $111.92 | $108.80 | $109.62 | 1.78M |
| Oct 12, 2026 | $110.19 | $112.43 | $109.96 | $111.08 | 1.66M |
| Oct 9, 2026 | $109.70 | $112.65 | $109.70 | $110.42 | 1.85M |
| Oct 8, 2026 | $109.41 | $110.64 | $107.41 | $109.84 | 2.49M |
| Oct 7, 2026 | $111.62 | $113.995 | $110.1572 | $110.79 | 2.18M |
| Oct 6, 2026 | $108.87 | $111.245 | $107.43 | $109.72 | 1.77M |
| Oct 5, 2026 | $109.62 | $109.87 | $107.68 | $108.31 | 1.86M |
| Oct 2, 2026 | $106.96 | $109.99 | $106.65 | $109.86 | 2.6M |
| Oct 1, 2026 | $109.93 | $110.50 | $106.84 | $106.94 | 2.33M |
| Sep 30, 2026 | $111.54 | $112.45 | $110.35 | $110.40 | 3.52M |
| Sep 29, 2026 | $112.89 | $114.52 | $111.03 | $111.56 | 2.87M |
| Sep 28, 2026 | $113.34 | $113.9399 | $112.10 | $112.89 | 2.24M |
| Sep 25, 2026 | $115.36 | $115.625 | $113.43 | $113.90 | 1.96M |
| Sep 24, 2026 | $112.13 | $116.0899 | $111.0701 | $115.22 | 3.17M |
| Sep 23, 2026 | $116.845 | $116.845 | $112.18 | $112.44 | 2.7M |
| Sep 22, 2026 | $111.50 | $115.18 | $110.95 | $115.13 | 4.15M |
| Sep 21, 2026 | $112.80 | $113.47 | $111.05 | $111.45 | 2.88M |
| Sep 18, 2026 | $109.72 | $112.66 | $109.3779 | $112.45 | 10.18M |
| Sep 17, 2026 | $107.08 | $110.8799 | $106.82 | $109.68 | 1.98M |
| Sep 16, 2026 | $106.66 | $109.63 | $105.50 | $108.44 | 1.71M |
Latest HALO news
The latest Smart Investors Daily articles mentioning HALO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
HALO research
Overview
Company profile and research snapshot.
Company profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $73.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 8, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 8, 2026 | JP Morgan | Neutral | — |
| Sep 2, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 8, 2026
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.
Yahoo · Oct 8, 2026
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
Benzinga · Oct 8, 2026
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
